Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Popular weight loss drugs such as Wegovy and Zepbound have shown incredible success in clinical trials. But in the real world ...

Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.

Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

The American Medical Association's House of Delegates passed an Endocrine Society resolution that aims to improve access to ...

New research suggests a link between some weight loss drugs and potentially blinding eye diseases. That risk is especially high for older adults. A recent study found that older adults with diabetes ...